600276 恒瑞医药
已收盘 03-26 15:00:00
资讯
新帖
简况
恒瑞医药(01276)拟向上海瑞宏迪增资2.85亿元
智通财经 · 03-25 23:20
恒瑞医药(01276)拟向上海瑞宏迪增资2.85亿元
先声药业(02096)：周云曙获委任为首席执行官
智通财经 · 03-25 23:02
先声药业(02096)：周云曙获委任为首席执行官
恒瑞医药2025年年报：营收净利再创新高 创新国际化双轮驱动结硕果
21世纪经济报道 · 03-25 22:22
恒瑞医药2025年年报：营收净利再创新高 创新国际化双轮驱动结硕果
恒瑞医药：2025年净利润同比增长21.69%，拟10派2元
老虎资讯综合 · 03-25 20:47
恒瑞医药：2025年净利润同比增长21.69%，拟10派2元
恒瑞医药(600276.SH)：SHR-3836注射液获得药物临床试验批
智通财经 · 03-20
恒瑞医药(600276.SH)：SHR-3836注射液获得药物临床试验批
恒瑞医药：1类新药注射用瑞康曲妥珠单抗新增乳腺癌适应症获批
每日经济新闻 · 03-20
恒瑞医药：1类新药注射用瑞康曲妥珠单抗新增乳腺癌适应症获批
恒瑞医药(600276.SH)：富马酸立康可泮(HRS-5965)胶囊药品上市许可申请获受理
智通财经 · 03-16
恒瑞医药(600276.SH)：富马酸立康可泮(HRS-5965)胶囊药品上市许可申请获受理
恒瑞医药(600276.SH)：SHR-1819注射液联合SHR-1905注射液用于治疗特应性皮炎获批开展临床试验
智通财经 · 03-16
恒瑞医药(600276.SH)：SHR-1819注射液联合SHR-1905注射液用于治疗特应性皮炎获批开展临床试验
恒瑞医药获Wellington Management Group LLP增持4.96万股
新浪港股 · 03-15
恒瑞医药获Wellington Management Group LLP增持4.96万股
恒瑞医药自主研发1类创新药海曲泊帕乙醇胺片获NMPA批准新增适应症
美股速递 · 03-13
恒瑞医药自主研发1类创新药海曲泊帕乙醇胺片获NMPA批准新增适应症
Wellington Management Group LLP增持恒瑞医药(01276)4.96万股 每股作价约66.13港元
智通财经 · 03-13
Wellington Management Group LLP增持恒瑞医药(01276)4.96万股 每股作价约66.13港元
恒瑞医药(600276.SH)：盐酸伊立替康脂质体注射液(Ⅱ)获批临床试验
智通财经 · 03-13
恒瑞医药(600276.SH)：盐酸伊立替康脂质体注射液(Ⅱ)获批临床试验
恒瑞医药(600276.SH)：1类创新药海曲泊帕乙醇胺片新增适应症
智通财经 · 03-13
恒瑞医药(600276.SH)：1类创新药海曲泊帕乙醇胺片新增适应症
恒瑞医药：舒地胰岛素诺利糖肽注射液上市许可申请获国家药监局受理
每日经济新闻 · 03-13
恒瑞医药：舒地胰岛素诺利糖肽注射液上市许可申请获国家药监局受理
恒瑞医药：注射用SHR-9803获临床试验批准
南方财经网 · 03-11
恒瑞医药：注射用SHR-9803获临床试验批准
英硅智能与Liquid AI达成合作；氢溴酸他泽司他片被召回
21世纪经济报道 · 03-10
英硅智能与Liquid AI达成合作；氢溴酸他泽司他片被召回
恒瑞医药：HRS9531注射液获临床试验批准
南方财经网 · 03-09
恒瑞医药：HRS9531注射液获临床试验批准
“十五五”将谋划约千个紧密型县域医共体建设；先维盈 获批上市
21世纪经济报道 · 03-09
“十五五”将谋划约千个紧密型县域医共体建设；先维盈 获批上市
恒瑞医药(600276.SH)子公司阿得贝利单抗注射液获批开展临床试验
智通财经网 · 03-06
恒瑞医药(600276.SH)子公司阿得贝利单抗注射液获批开展临床试验
港股恒瑞医药涨超6%
每日经济新闻 · 03-05
港股恒瑞医药涨超6%
加载更多
公司概况
公司名称：
江苏恒瑞医药股份有限公司
所属行业：
医药制造业
上市日期：
2000-10-18
主营业务：
江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。
发行价格：
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":51.63,"timestamp":1774508400000,"preClose":54.1,"halted":0,"volume":64941653,"delay":0,"changeRate":-0.0457,"floatShares":6379000000,"shares":6637000000,"eps":1.1252,"marketStatus":"已收盘","change":-2.47,"latestTime":"03-26 15:00:00","open":53.28,"high":54.1,"low":51.54,"amount":3413000000,"amplitude":0.0473,"askPrice":51.64,"askSize":38,"bidPrice":51.63,"bidSize":45,"shortable":0,"etf":0,"ttmEps":1.1252,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774575000000},"marketStatusCode":5,"adr":0,"adjPreClose":54.1,"symbolType":"stock","openAndCloseTimeList":[[1774488600000,1774495800000],[1774501200000,1774508400000]],"highLimit":59.51,"lowLimit":48.69,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":5.59,"roa":"--","peRate":45.885176,"roe":"14.26%","epsLYR":1,"committee":-0.100855,"marketValue":342679000000,"turnoverRate":0.0102,"status":1,"hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":61.2,"timestamp":1774512000005,"preClose":63.35,"halted":0,"volume":2069600,"auction":3,"delay":0,"premium":"+4.74"},"floatMarketCap":329348000000},"requestUrl":"/m/hq/s/600276","defaultTab":"news","newsList":[{"id":"2622678070","title":"恒瑞医药(01276)拟向上海瑞宏迪增资2.85亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622678070","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622678070?lang=zh_cn&edition=full","pubTime":"2026-03-25 23:20","pubTimestamp":1774452011,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 公布，于2026年3月25日，公司与恒瑞集团、盛迪生物医药基金、深圳迎泰及上海瑞宏迪订立增资协议，以将上海瑞宏迪的注册资本由约人民币1.316亿元增加至约2.303亿元。根据增资协议，公司、恒瑞集团、盛迪生物医药基金及深圳迎泰同意按比例以现金形式出资合共人民币7.5亿元，该公司出资2.85亿元。增资协议完成后，公司、恒瑞集团、盛迪生物医药基金及深圳迎泰将分别继续持有上海瑞宏迪38.0%、28.0%、19.0%及15.0%的股权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419126.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359201885.HKD","LU2543165471.USD","LU2580892789.USD","LU2148510915.USD","LU2097828474.EUR","LU1146622755.USD","LU2097828714.EUR","LU1997245094.SGD","LU2289578879.USD","01276","LU1064131003.USD","BK0196","LU1997245177.USD","LU0405327494.USD","LU2328871848.SGD","LU2580892862.HKD","600276","LU1820825898.SGD","LU1328615791.USD","LU0405327148.USD","BK0060","BK0239","LU1580142542.USD","LU2097828557.USD","LU2495084118.USD","LU2097828805.USD","BK0028","LU1781817850.SGD","LU1655091616.SGD","LU1023057109.AUD","LU2097828631.EUR","LU1255011170.USD","LU0359202008.SGD","LU2488822045.USD","BK1191","BK0188","LU0359201612.USD","BK0183","LU1969619763.USD","LU1997244956.HKD","BK0012","LU1064130708.USD"],"gpt_icon":0},{"id":"2622772640","title":"先声药业(02096)：周云曙获委任为首席执行官","url":"https://stock-news.laohu8.com/highlight/detail?id=2622772640","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622772640?lang=zh_cn&edition=full","pubTime":"2026-03-25 23:02","pubTimestamp":1774450923,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业(02096)发布公告，周云曙博士已获委任为首席执行官，自2026年3月25日起生效。在此职务中，彼作为高级管理人员，负责监督本集团业务营运的整体管理。周博士向董事会汇报，并须接受董事会的指导及监督。为专注集团长期战略制定、重大投资决策及监督董事会履职，任晋生先生将自2026年3月25日起不再担任首席执行官。任先生将继续担任公司董事长兼执行董事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419110.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1580142542.USD","LU1997245177.USD","BK1191","BK0239","BK0196","LU2580892862.HKD","LU2097828805.USD","LU0405327494.USD","LU1655091616.SGD","LU2495084118.USD","LU2289578879.USD","LU2148510915.USD","LU2097828714.EUR","LU1064131003.USD","LU1255011170.USD","02096","BK0060","LU1064130708.USD","BK0028","LU1997244956.HKD","BK1583","LU2488822045.USD","BK0183","LU1820825898.SGD","LU1328615791.USD","LU2097828474.EUR","LU1969619763.USD","LU2328871848.SGD","BK0012","LU1997245094.SGD","LU1781817850.SGD","LU2097828557.USD","600276","LU2097828631.EUR","BK0188","LU0405327148.USD","LU1146622755.USD","LU2580892789.USD"],"gpt_icon":0},{"id":"2622072044","title":"恒瑞医药2025年年报：营收净利再创新高 创新国际化双轮驱动结硕果","url":"https://stock-news.laohu8.com/highlight/detail?id=2622072044","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622072044?lang=zh_cn&edition=full","pubTime":"2026-03-25 22:22","pubTimestamp":1774448520,"startTime":"0","endTime":"0","summary":"3月25日，恒瑞医药发布2025年年度报告。报告期内，公司坚持“科技创新+国际化”双轮驱动战略，实现业绩持续增长，营收和净利均再创新高。全年实现营业收入316.29亿元，同比增长13.02%；归属于上市公司股东的净利润77.11亿元，同比增长21.69%；归属于上市公司股东的扣除非经常性损益的净利润74.13亿元，同比增长20.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603253684444032.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603253684444032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01276","600276"],"gpt_icon":0},{"id":"1167610912","title":"恒瑞医药：2025年净利润同比增长21.69%，拟10派2元","url":"https://stock-news.laohu8.com/highlight/detail?id=1167610912","media":"老虎资讯综合","labels":["dataReport"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167610912?lang=zh_cn&edition=full","pubTime":"2026-03-25 20:47","pubTimestamp":1774442842,"startTime":"0","endTime":"0","summary":"3月25日，$恒瑞医药(01276)$公告称，2025年公司实现营收316.29亿元，同比增长13.02%；净利润77.11亿元，同比增长21.69%。拟向全体股东按每10股派发现金股利2.00元（含税）。小财注：Q3净利润13.01亿，据此计算，Q4净利润19.6亿，环比增长50%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"324431b18d184842b2237adf08e51534","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恒瑞医药：2025年净利润同比增长21.69%，拟10派2元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","BK0239","BK0183","01276","LU1580142542.USD","LU1781817850.SGD","LU2488822045.USD","LU1328615791.USD","BK0196","LU1255011170.USD","LU2097828557.USD","LU2097828631.EUR","LU1997245177.USD","LU2495084118.USD","LU2097828805.USD","LU2543165471.USD","LU1969619763.USD","LU2097828474.EUR","LU1997244956.HKD","BK0060","600276","LU2148510915.USD","LU1820825898.SGD","LU2289578879.USD","LU1655091616.SGD","LU1064131003.USD","BK0028","BK0188","LU0359202008.SGD","LU1023057109.AUD","LU1997245094.SGD","LU0405327494.USD","LU2580892862.HKD","LU0359201885.HKD","LU0405327148.USD","LU1064130708.USD","BK0012","BK1191","LU1146622755.USD","LU2097828714.EUR","LU2580892789.USD","LU0359201612.USD"],"gpt_icon":0},{"id":"2620978152","title":"恒瑞医药(600276.SH)：SHR-3836注射液获得药物临床试验批","url":"https://stock-news.laohu8.com/highlight/detail?id=2620978152","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620978152?lang=zh_cn&edition=full","pubTime":"2026-03-20 17:10","pubTimestamp":1773997815,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司上海恒瑞医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于SHR-3836注射液的《药物临床试验批准通知书》，将于近期开展临床试验。SHR-3836注射液是公司自主研发的创新型抗肿瘤药物，拟用于治疗多发性骨髓瘤。经查询，目前国内外尚无同类药上市。截至目前，SHR-3836注射液相关项目累计研发投入约3,170万元(未经审计)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","LU0405327148.USD","LU1255011170.USD","LU0405327494.USD","LU0359201885.HKD","LU2097828714.EUR","BK0028","600276","LU0359202008.SGD","LU1064131003.USD","LU1146622755.USD","LU1997245094.SGD","LU2097828557.USD","LU2097828631.EUR","BK1191","LU2328871848.SGD","LU1580142542.USD","LU2488822045.USD","LU2580892862.HKD","LU1655091616.SGD","LU1820825898.SGD","LU2148510915.USD","LU1997244956.HKD","BK0196","LU2097828474.EUR","LU2097828805.USD","LU2289578879.USD","LU1997245177.USD","LU2495084118.USD","LU2580892789.USD","LU1969619763.USD","BK0239","LU1023057109.AUD","LU1328615791.USD","BK0060","LU1064130708.USD","LU1781817850.SGD","LU2543165471.USD","LU0359201612.USD","01276","BK0012","BK0188"],"gpt_icon":0},{"id":"2620378159","title":"恒瑞医药：1类新药注射用瑞康曲妥珠单抗新增乳腺癌适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2620378159","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620378159?lang=zh_cn&edition=full","pubTime":"2026-03-20 17:09","pubTimestamp":1773997757,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月20日，恒瑞医药(600276.SH)公告称，公司子公司苏州盛迪亚生物医药有限公司收到国家药监局通知，批准其自主研发的1类创新药注射用瑞康曲妥珠单抗(SHR-A1811)新增适应症，用于治疗既往接受过一种或以上抗HER2药物治疗的局部晚期或转移性HER2阳性成人乳腺癌患者。该药已于2025年5月首次获批用于HER2突变非小细胞肺癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603203678970213.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603203678970213.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2289578879.USD","LU1655091616.SGD","BK0188","LU2495084118.USD","LU1997245177.USD","LU1969619763.USD","LU1064131003.USD","LU1820825898.SGD","LU0359201885.HKD","BK0012","BK0060","BK1191","LU1997244956.HKD","LU1781817850.SGD","BK0028","LU0405327494.USD","LU1064130708.USD","LU2097828631.EUR","LU1255011170.USD","LU2543165471.USD","LU1023057109.AUD","LU2580892789.USD","600276","LU2097828714.EUR","BK0183","LU1146622755.USD","LU1580142542.USD","BK0196","LU0359202008.SGD","BK0239","LU1328615791.USD","LU0405327148.USD","LU2097828474.EUR","LU2097828805.USD","LU2488822045.USD","LU2580892862.HKD","01276","LU2097828557.USD","LU2328871848.SGD","LU0359201612.USD","LU1997245094.SGD","LU2148510915.USD"],"gpt_icon":0},{"id":"2619645660","title":"恒瑞医药(600276.SH)：富马酸立康可泮(HRS-5965)胶囊药品上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2619645660","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619645660?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:22","pubTimestamp":1773652966,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，公司子公司成都盛迪医药有限公司收到国家药品监督管理局下发的《受理通知书》，公司富马酸立康可泮胶囊的药品上市许可申请获国家药监局受理。富马酸立康可泮胶囊是一种补体因子B抑制剂，可抑制补体介导的血管内外溶血反应，提升血红蛋白水平。截至目前，HRS-5965胶囊相关项目累计研发投入约25,150万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414336.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1820825898.SGD","LU2328871848.SGD","LU2097828631.EUR","LU1064130708.USD","BK0183","LU0359201612.USD","LU2097828714.EUR","BK0060","LU1781817850.SGD","LU2580892789.USD","LU2097828557.USD","LU1328615791.USD","LU2488822045.USD","LU0359202008.SGD","LU1997245177.USD","LU1580142542.USD","LU1146622755.USD","LU2097828474.EUR","LU1997244956.HKD","LU2580892862.HKD","600276","LU1655091616.SGD","BK0239","LU1255011170.USD","BK0012","LU1997245094.SGD","LU0405327148.USD","LU2097828805.USD","LU1023057109.AUD","BK0196","LU2148510915.USD","LU2543165471.USD","LU2495084118.USD","LU0359201885.HKD","BK1191","LU1969619763.USD","LU1064131003.USD","01276","LU0405327494.USD","BK0028","BK0188","LU2289578879.USD"],"gpt_icon":0},{"id":"2619565624","title":"恒瑞医药(600276.SH)：SHR-1819注射液联合SHR-1905注射液用于治疗特应性皮炎获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2619565624","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619565624?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:17","pubTimestamp":1773652643,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司广东恒瑞医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于SHR-1819注射液、SHR-1905注射液的《药物临床试验批准通知书》。经审查，2025年12月18日受理的SHR-1819注射液、SHR-1905注射液符审批结论合药品注册的有关要求，同意开展临床试验。申请的适应症：SHR-1819注射液联合SHR-1905注射液用于治疗特应性皮炎。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK0239","LU1023057109.AUD","LU1997245094.SGD","LU2097828714.EUR","LU1580142542.USD","LU2488822045.USD","LU2580892789.USD","LU1064130708.USD","BK0196","BK0183","LU2543165471.USD","01276","LU0359202008.SGD","LU0359201885.HKD","LU2097828805.USD","LU2495084118.USD","LU1064131003.USD","LU1328615791.USD","LU1655091616.SGD","LU1969619763.USD","600276","BK0060","LU2148510915.USD","LU1997245177.USD","BK0028","LU2580892862.HKD","LU1997244956.HKD","LU1255011170.USD","LU0405327148.USD","LU2097828474.EUR","LU0405327494.USD","BK0012","LU1820825898.SGD","LU0359201612.USD","LU2289578879.USD","LU1781817850.SGD","LU2097828557.USD","LU1146622755.USD","LU2097828631.EUR","LU2328871848.SGD","BK0188"],"gpt_icon":0},{"id":"2619170749","title":"恒瑞医药获Wellington Management Group LLP增持4.96万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2619170749","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619170749?lang=zh_cn&edition=full","pubTime":"2026-03-15 15:28","pubTimestamp":1773559680,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 香港联交所最新数据显示，3月11日，Wellington Management Group LLP增持恒瑞医药（01276）4.96万股，每股作价66.1267港元，总金额约为327.99万港元。增持后最新持股数目约为2324.44万股，持股比例为9.00%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-03-15/doc-inhqzzfv9634355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0183","LU1997245177.USD","BK1191","LU1023057109.AUD","BK0188","LU1655091616.SGD","LU1820825898.SGD","LU1064131003.USD","BK0012","600276","LU0405327494.USD","LU1064130708.USD","LU2543165471.USD","LU2495084118.USD","LU2328871848.SGD","BK0196","LU0359201612.USD","LU0359202008.SGD","LU1328615791.USD","LU0405327148.USD","LU2097828714.EUR","LU1997244956.HKD","BK0239","LU2097828631.EUR","LU1969619763.USD","LU0359201885.HKD","LU2580892789.USD","LU2148510915.USD","LU1146622755.USD","LU2488822045.USD","LU2097828474.EUR","LU1781817850.SGD","BK0028","LU2580892862.HKD","LU1255011170.USD","LU1580142542.USD","01276","LU1997245094.SGD","BK0060","LU2097828557.USD","LU2097828805.USD","LU2289578879.USD"],"gpt_icon":0},{"id":"1104409846","title":"恒瑞医药自主研发1类创新药海曲泊帕乙醇胺片获NMPA批准新增适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=1104409846","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104409846?lang=zh_cn&edition=full","pubTime":"2026-03-13 19:25","pubTimestamp":1773401111,"startTime":"0","endTime":"0","summary":"国家药品监督管理局（NMPA）已正式批准恒瑞医药自主研发的1类创新药——海曲泊帕乙醇胺片增加新的适应症。此次获批标志着该药物在临床应用中迈出重要一步，有望为更多患者提供治疗选择。\n海曲泊帕乙醇胺片作为一种创新药物，其新增适应症的获批进一步拓展了该药的应用范围，彰显了恒瑞医药在创新药研发领域的持续投入与实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1820825898.SGD","LU1255011170.USD","BK0239","BK0028","LU2580892862.HKD","BK0060","LU1969619763.USD","LU1328615791.USD","LU1064131003.USD","LU1655091616.SGD","LU1997245094.SGD","LU2097828714.EUR","BK0196","LU1997244956.HKD","BK0183","BK0188","BK0012","LU2097828557.USD","LU2148510915.USD","LU1580142542.USD","LU2097828474.EUR","LU2328871848.SGD","LU2488822045.USD","600276","LU0405327494.USD","LU1146622755.USD","LU1781817850.SGD","LU1997245177.USD","LU2580892789.USD","LU2289578879.USD","LU2097828805.USD","LU2097828631.EUR","LU0405327148.USD","LU2495084118.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2619919761","title":"Wellington Management Group LLP增持恒瑞医药(01276)4.96万股 每股作价约66.13港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2619919761","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619919761?lang=zh_cn&edition=full","pubTime":"2026-03-13 19:19","pubTimestamp":1773400763,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，3月11日，Wellington Management Group LLP增持恒瑞医药(01276)4.96万股，每股作价66.1267港元，总金额约为327.99万港元。增持后最新持股数目约为2324.44万股，持股比例为9.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413771.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01276","BK0196","LU1146622755.USD","LU1064130708.USD","BK0060","LU2097828631.EUR","BK0012","LU1580142542.USD","BK0239","BK0188","LU0359201612.USD","LU2097828557.USD","LU0359202008.SGD","LU1997244956.HKD","600276","LU1255011170.USD","LU1997245177.USD","LU1820825898.SGD","LU2097828714.EUR","LU2488822045.USD","LU2289578879.USD","LU2580892789.USD","LU2328871848.SGD","BK1191","LU1023057109.AUD","LU2580892862.HKD","LU1969619763.USD","LU2543165471.USD","LU1655091616.SGD","LU2097828474.EUR","LU1064131003.USD","LU1781817850.SGD","BK0028","LU2148510915.USD","LU1997245094.SGD","LU0359201885.HKD","LU1328615791.USD","LU2097828805.USD","LU2495084118.USD","BK0183","LU0405327494.USD","LU0405327148.USD"],"gpt_icon":0},{"id":"2619193393","title":"恒瑞医药(600276.SH)：盐酸伊立替康脂质体注射液(Ⅱ)获批临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2619193393","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619193393?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:49","pubTimestamp":1773395351,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司上海恒瑞医药有限公司收到国家药品监督管理局核准签发关于盐酸伊立替康脂质体注射液(Ⅱ)的《药物临床试验批准通知书》，将于近期开展临床试验。根据《中华人民共和国药品管理法》及有关规定，经审查，2025年12月25日受理的盐酸伊立替康脂质体注射液(Ⅱ)临床试验申请符合药品注册的有关要求，同意开展本项临床试验。具体为：HR070803联合奥沙利铂、5-氟尿嘧啶、亚叶酸钙对比吉西他滨联合卡培他滨用于胰腺癌术后辅助治疗的随机、开放、平行对照、多中心Ⅲ期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1580142542.USD","LU1781817850.SGD","LU2580892862.HKD","LU1328615791.USD","LU1997245177.USD","600276","LU1064131003.USD","LU0405327494.USD","LU2289578879.USD","BK0183","LU0359201612.USD","LU2097828631.EUR","BK0060","LU1023057109.AUD","BK0028","LU2097828557.USD","LU0405327148.USD","BK1191","LU1064130708.USD","LU2148510915.USD","LU2580892789.USD","LU1969619763.USD","BK0188","LU2543165471.USD","LU0359201885.HKD","LU0359202008.SGD","LU2097828714.EUR","BK0012","LU1255011170.USD","BK0239","LU1820825898.SGD","LU2097828474.EUR","LU1997245094.SGD","LU1997244956.HKD","LU2328871848.SGD","01276","LU2097828805.USD","LU2495084118.USD","LU2488822045.USD","BK0196","LU1146622755.USD","LU1655091616.SGD"],"gpt_icon":0},{"id":"2619198064","title":"恒瑞医药(600276.SH)：1类创新药海曲泊帕乙醇胺片新增适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2619198064","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619198064?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:43","pubTimestamp":1773395002,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司收到国家药品监督管理局的通知，批准公司自主研发的1类创新药海曲泊帕乙醇胺片新增适应症。批准的适应症：本品联合免疫抑制治疗适用于15岁及以上初治重型再生障碍性贫血(SAA)患者。海曲泊帕乙醇胺片于2021年获批上市两个适应症：1.本品适用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症(ITP)成人患者。2.本品适用于对免疫抑制治疗(IST)疗效不佳的重型再生障碍性贫血(SAA)成人患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1023057109.AUD","LU0359201885.HKD","LU1580142542.USD","LU2097828714.EUR","LU2097828474.EUR","LU1655091616.SGD","LU2097828631.EUR","BK1161","LU1146622755.USD","LU0405327148.USD","LU0359202008.SGD","LU2289578879.USD","LU0359201612.USD","LU2148510915.USD","LU1328615791.USD","159992","BK0239","LU2543165471.USD","LU2580892789.USD","LU2488822045.USD","LU2328871848.SGD","LU1997245094.SGD","LU1820825898.SGD","BK0183","BK0188","LU2097828805.USD","LU2495084118.USD","LU1064130708.USD","BK1574","LU1997245177.USD","BK0196","BK0028","BK1191","LU2580892862.HKD","06978","LU2097828557.USD","LU1064131003.USD","BK0060","LU1781817850.SGD","600276","LU1969619763.USD","LU1255011170.USD","01276","LU1997244956.HKD","LU0405327494.USD","BK0012"],"gpt_icon":0},{"id":"2619987211","title":"恒瑞医药：舒地胰岛素诺利糖肽注射液上市许可申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2619987211","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619987211?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:39","pubTimestamp":1773394783,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月13日，恒瑞医药(600276.SH)公告称，公司收到国家药监局下发的《受理通知书》，公司舒地胰岛素诺利糖肽注射液的上市许可申请获国家药监局受理。该药品适用于血糖控制不佳的成人2型糖尿病患者，在饮食和运动基础上联合其他口服降糖药物，改善血糖控制。该药品是公司自主研发的由长效基础胰岛素类似物和胰高血糖素样肽-1受体激动剂组成的固定比例复方制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603133671602785.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603133671602785.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01276","BK0196","LU1146622755.USD","LU1064130708.USD","BK0060","LU2097828631.EUR","BK0012","LU1580142542.USD","BK0239","BK0188","LU0359201612.USD","LU2097828557.USD","LU0359202008.SGD","LU1997244956.HKD","600276","LU1255011170.USD","LU1997245177.USD","LU1820825898.SGD","LU2097828714.EUR","LU2488822045.USD","LU2289578879.USD","LU2580892789.USD","LU2328871848.SGD","BK1191","LU1023057109.AUD","LU2580892862.HKD","LU1969619763.USD","LU2543165471.USD","LU1655091616.SGD","LU2097828474.EUR","LU1064131003.USD","LU1781817850.SGD","BK0028","LU2148510915.USD","LU1997245094.SGD","LU0359201885.HKD","LU1328615791.USD","LU2097828805.USD","LU2495084118.USD","BK0183","LU0405327494.USD","LU0405327148.USD"],"gpt_icon":0},{"id":"2618675910","title":"恒瑞医药：注射用SHR-9803获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2618675910","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618675910?lang=zh_cn&edition=full","pubTime":"2026-03-11 17:07","pubTimestamp":1773220033,"startTime":"0","endTime":"0","summary":"【恒瑞医药：注射用SHR-9803获临床试验批准】恒瑞医药公告，注射用SHR-9803收到国家药品监督管理局签发的《药物临床试验批准通知书》（受理号：CXSL2501078），同意本品联合阿得贝利单抗±贝伐珠单抗±化疗在晚期恶性实体瘤患者中开展临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603113668861077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","LU1064130708.USD","LU2097828805.USD","LU1064131003.USD","BK0188","LU0359201612.USD","LU1146622755.USD","LU2543165471.USD","LU1997245177.USD","600276","LU1023057109.AUD","BK0183","LU2488822045.USD","LU2097828557.USD","LU0405327148.USD","LU2148510915.USD","LU2495084118.USD","LU2097828714.EUR","LU0405327494.USD","LU2097828474.EUR","LU2580892789.USD","LU0359201885.HKD","LU2289578879.USD","LU2097828631.EUR","LU1969619763.USD","BK1191","LU1655091616.SGD","LU1820825898.SGD","BK0060","BK0028","BK0239","LU1781817850.SGD","LU1328615791.USD","LU1997244956.HKD","LU2580892862.HKD","LU1255011170.USD","LU1997245094.SGD","BK0012","LU1580142542.USD","LU0359202008.SGD","01276","LU2328871848.SGD"],"gpt_icon":0},{"id":"2618055516","title":"英硅智能与Liquid AI达成合作；氢溴酸他泽司他片被召回","url":"https://stock-news.laohu8.com/highlight/detail?id=2618055516","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618055516?lang=zh_cn&edition=full","pubTime":"2026-03-10 08:03","pubTimestamp":1773101006,"startTime":"0","endTime":"0","summary":"政策动向氢溴酸他泽司他片启动召回程序国家医保局3月9日消息显示，和黄医药（中国）有限公司发布公告，对其授权引进产品氢溴酸他泽司他片（商品名：达唯珂）启动撤市及产品召回程序。据此，自2026年3月9日起，撤销氢溴酸他泽司他片在全国各省级医药采购平台挂网，并根据企业申请，将氢溴酸他泽司他片移出《商业健康保险创新药品目录（2025年）》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103666774021.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103666774021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828631.EUR","600276","LU0405327148.USD","BK4160","LU2580892862.HKD","BK0183","LU1997244956.HKD","002422","BK0175","LU2495084118.USD","BK0060","TSLP","LU2328871848.SGD","LU1969619763.USD","LU1580142542.USD","BK0096","LU2097828714.EUR","LU2580892789.USD","BK0216","600196","BK0188","BK0196","LU2097828557.USD","LU1997245177.USD","LU2289578879.USD","BK0239","688621","LU2097828474.EUR","LU1979443071.USD","LU1064130708.USD","LU1934453819.USD","LU2097828805.USD","LU1146622755.USD","LU2148510915.USD","BK0028","LU1820825898.SGD","LU1781817850.SGD","BK0012","GIPR","LU1064131003.USD","BK0187","LU1997245094.SGD","LU0405327494.USD","LU1328615791.USD","LU1255011170.USD","LU2488822045.USD","LU1655091616.SGD","IND"],"gpt_icon":0},{"id":"2618641017","title":"恒瑞医药：HRS9531注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2618641017","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618641017?lang=zh_cn&edition=full","pubTime":"2026-03-09 17:27","pubTimestamp":1773048469,"startTime":"0","endTime":"0","summary":"南财智讯3月9日电，恒瑞医药公告，HRS9531注射液收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意本品开展慢性肾脏病（CKD）的临床试验。通知书审批结论显示，该申请于2025年12月9日受理，符合药品注册有关要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603093666153269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0405327148.USD","LU2488822045.USD","600276","LU1969619763.USD","LU0359202008.SGD","LU1064130708.USD","01276","LU2097828714.EUR","LU1064131003.USD","LU1023057109.AUD","LU1997245177.USD","LU2580892862.HKD","LU2097828631.EUR","LU2289578879.USD","BK0012","BK0060","LU1820825898.SGD","LU2097828474.EUR","BK0239","LU1997244956.HKD","BK0196","LU2543165471.USD","LU2580892789.USD","LU0405327494.USD","LU2495084118.USD","LU2097828557.USD","BK1191","LU1580142542.USD","LU1146622755.USD","LU1255011170.USD","BK0028","LU1328615791.USD","LU2328871848.SGD","LU1781817850.SGD","BK0183","LU2097828805.USD","LU1655091616.SGD","LU1997245094.SGD","LU0359201885.HKD","LU2148510915.USD","LU0359201612.USD","BK0188"],"gpt_icon":0},{"id":"2618113692","title":"“十五五”将谋划约千个紧密型县域医共体建设；先维盈 获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2618113692","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618113692?lang=zh_cn&edition=full","pubTime":"2026-03-09 08:07","pubTimestamp":1773014820,"startTime":"0","endTime":"0","summary":"这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！政策动向国家卫健委：“十五五”期间将谋划1000个左右紧密型县域医共体建设3月7日，十四届全国人大 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260309/c675145878.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260309/c675145878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["002653","LU1997244956.HKD","LU1146622755.USD","LU1655091616.SGD","LU2495084118.USD","BK0028","LU0405327148.USD","LU2097828557.USD","LU0405327494.USD","LU2148510915.USD","BK0188","LU1997245094.SGD","LU2289578879.USD","BK0183","LU1064131003.USD","LU2328871848.SGD","LU2097828714.EUR","LU1328615791.USD","LU1064130708.USD","LU2580892789.USD","BK0196","BK0060","LU1781817850.SGD","LU1820825898.SGD","LU2488822045.USD","LU1580142542.USD","BK0033","LU1997245177.USD","LU1255011170.USD","LU2097828631.EUR","688177","LU2097828474.EUR","600276","LU2580892862.HKD","LU2097828805.USD","BK0077","LU1969619763.USD","BK0012","BK0239"],"gpt_icon":0},{"id":"2617850276","title":"恒瑞医药(600276.SH)子公司阿得贝利单抗注射液获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2617850276","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617850276?lang=zh_cn&edition=full","pubTime":"2026-03-06 17:17","pubTimestamp":1772788650,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，公司子公司上海盛迪医药有限公司收到国家药品监督管理局核准签发关于阿得贝利单抗注射液的《药物临床试验批准通知书》，将于近期开展临床试验。根据《中华人民共和国药品管理法》及有关规定，经审查，2025年12月8日受理的阿得贝利单抗注射液符合药品注册的有关要求，同意本品开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411010.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU2289578879.USD","LU1655091616.SGD","BK0188","LU2495084118.USD","LU1997245177.USD","LU1969619763.USD","LU1064131003.USD","LU1820825898.SGD","LU0359201885.HKD","BK0012","BK0060","BK1191","LU1997244956.HKD","LU1781817850.SGD","BK0028","LU0405327494.USD","LU1064130708.USD","LU2097828631.EUR","LU1255011170.USD","LU2543165471.USD","LU1023057109.AUD","LU2580892789.USD","600276","LU2097828714.EUR","BK0183","LU1146622755.USD","LU1580142542.USD","BK0196","LU0359202008.SGD","BK0239","LU1328615791.USD","LU0405327148.USD","LU2097828474.EUR","LU2097828805.USD","LU2488822045.USD","LU2580892862.HKD","01276","LU2097828557.USD","LU2328871848.SGD","LU0359201612.USD","LU1997245094.SGD","LU2148510915.USD"],"gpt_icon":0},{"id":"2617559182","title":"港股恒瑞医药涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617559182","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617559182?lang=zh_cn&edition=full","pubTime":"2026-03-05 10:58","pubTimestamp":1772679537,"startTime":"0","endTime":"0","summary":"每经AI快讯，恒瑞医药(01276.HK)涨超6%，截至发稿，涨6.15%，报63.9港元，成交额1.13亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603053662905861.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603053662905861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01276","BK0183","BK4588","LU1997244956.HKD","600276","LU2328871848.SGD","LU1997245094.SGD","LU2495084118.USD","LU1023057109.AUD","LU1328615791.USD","BK4585","LU2097828631.EUR","LU2580892862.HKD","LU1969619763.USD","LU1997245177.USD","LU2148510915.USD","LU2580892789.USD","LU0359202008.SGD","LU1064131003.USD","LU2543165471.USD","LU0405327494.USD","BK0028","LU0359201885.HKD","VXUS","LU0359201612.USD","LU1580142542.USD","LU1255011170.USD","BK1191","LU1781817850.SGD","LU2097828805.USD","LU2097828557.USD","LU0405327148.USD","BK0239","BK0188","LU2097828714.EUR","LU1146622755.USD","LU1820825898.SGD","BK0012","BK0196","LU1655091616.SGD","LU2289578879.USD","VT","BK0060","LU2097828474.EUR","LU1064130708.USD","LU2488822045.USD"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774512054413,"stockEarnings":[{"period":"1week","weight":-0.0489},{"period":"1month","weight":-0.0709},{"period":"3month","weight":-0.1189},{"period":"6month","weight":-0.228},{"period":"1year","weight":0.21},{"period":"ytd","weight":-0.0918}],"compareEarnings":[{"period":"1week","weight":-0.0323},{"period":"1month","weight":-0.0368},{"period":"3month","weight":-0.007},{"period":"6month","weight":0.0271},{"period":"1year","weight":0.1667},{"period":"ytd","weight":-0.0093}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"449644人(较上一季度增加12.84%)","perCapita":"14186股","listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","registeredCapital":"663719万元","survey":" 江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。","listedPrice":11.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.1","shortVersion":"4.38.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}